EUVIMEDEUVIMED entdecken
Crossref

Lessons and Insights from a Case Study on Clinical Trial Fraud

Courtney McGuire, Jenn W Sellers, Cheryl Grandinetti, Michele Fedowitz, Kassa Ayalew

Therapeutic Innovation & Regulatory Science · 2026-05 · 60 (3) · 629-634

DOI: 10.1007/s43441-026-00939-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 09.03.2026. Verfasst von Courtney McGuire und 4 weiteren Autor:innen. Beteiligte Einrichtung: Office of Scientific Investigations (OSI), Office of Compliance (OC), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administrati…. Hauptthemen laut MEDLINE: Fraud, Clinical Trials as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The United States Food and Drug Administration Good Clinical Practice inspections play a critical role in safeguarding the rights, safety, and welfare of participants, verifying trial data, and ensuring regulatory compliance. Clinical trial fraud poses a serious threat to data integrity, undermines the reliability of regulatory decisions, and can jeopardize the protection of trial participants. This paper presents a case study of clinical trial fraud uncovered during preparations for a Food and Drug Administration inspection. It details the fraudulent activities committed, their impact on data integrity, and the consequences for the marketing application, and offers lessons learned and insights for preventing and detecting fraud in clinical trials. It emphasizes the application of Quality by Design principles by identifying critical factors that underpin clinical trial quality and designing and conducting the trials to protect those trial attributes. Additionally, it highlights the importance of risk-based strategies in monitoring, trial oversight, and the design and management of electronic systems. It also underscores the importance of reporting suspected clinical trial fraud to the Food and Drug Administration promptly. In this case, the Sponsor’s delay in reporting the fraudulent activities postponed the Food and Drug Administration’s investigation and ultimately extended the Prescription Drug User Fee Act timeline by three months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FraudClinical Trials as TopicUnited States Food and Drug AdministrationHumansUnited States

Stichwörter der Autor:innen

Clinical trial fraudData integrityGood clinical practice (GCP)U.S. FDA

Autor:innen und Institutionen

  • Office of Scientific Investigations (OSI), Office of Compliance (OC), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), 10903 New Hampshire Ave, WO51, Silver Spring, Maryland, 2099…

Zitieren

APA

McGuire, C., Sellers, J. W., Grandinetti, C., Fedowitz, M., & Ayalew, K. (2026). Lessons and Insights from a Case Study on Clinical Trial Fraud. Therapeutic Innovation & Regulatory Science, 60(3), 629-634. https://doi.org/10.1007/s43441-026-00939-7

Vancouver

McGuire C, Sellers JW, Grandinetti C, Fedowitz M, Ayalew K. Lessons and Insights from a Case Study on Clinical Trial Fraud. Therapeutic Innovation & Regulatory Science. 2026;60(3):629-634. doi:10.1007/s43441-026-00939-7

BibTeX
@article{McGuire2026,
  author = {McGuire, Courtney and Sellers, Jenn W and Grandinetti, Cheryl and Fedowitz, Michele and Ayalew, Kassa},
  title = {Lessons and Insights from a Case Study on Clinical Trial Fraud},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  volume = {60},
  number = {3},
  pages = {629--634},
  doi = {10.1007/s43441-026-00939-7}
}
Kostenlos starten →